ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
9
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
9
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Methylphenidate Extended Release Tablets Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-31I16985
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Methylphenidate Extended Release Tablets Market Research Report 2024
BUY CHAPTERS

Global Methylphenidate Extended Release Tablets Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-31I16985
Report
November 2025
Pages:127
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson
Novartis
Tris Pharma
Lannett Company
Noven Pharmaceuticals
Purdue Parma
Mallinckrodt plc
Ironshore Pharmaceuticals
Johnson & Johnson

Methylphenidate Extended Release Tablets Market

The global Methylphenidate Extended Release Tablets market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Methylphenidate Extended Release Tablets are a form of medication primarily used to manage symptoms of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. This medication functions as a central nervous system stimulant and works by increasing the levels of certain neurotransmitters in the brain, which enhances attention and focus while reducing impulsive and hyperactive behavior. The extended-release formulation of methylphenidate is designed to gradually release the drug into the bloodstream over an extended period, typically providing symptom relief for about 8 to 12 hours. This allows for consistent therapeutic effects throughout the day with a reduced need for multiple doses. It is essential for this medication to be taken under the supervision of a healthcare provider, as it requires careful dosage adjustments and monitoring for potential side effects.
From a downstream perspective, Hospital Pharmacy accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Methylphenidate Extended Release Tablets leading manufacturers including Johnson & Johnson, Novartis, Tris Pharma, Lannett Company, Noven Pharmaceuticals, Purdue Parma, Mallinckrodt, Ironshore Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Johnson & Johnson leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Methylphenidate Extended Release Tablets market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Methylphenidate Extended Release Tablets Market Report

Report Metric Details
Report Name Methylphenidate Extended Release Tablets Market
Segment by Type
  • 18mg
  • 27mg
  • 36mg
Segment by Application
  • Hospital Pharmacy
  • Retail Pharmacy
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Johnson & Johnson, Novartis, Tris Pharma, Lannett Company, Noven Pharmaceuticals, Purdue Parma, Mallinckrodt, Ironshore Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Methylphenidate Extended Release Tablets study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Methylphenidate Extended Release Tablets Market report?

Ans: The main players in the Methylphenidate Extended Release Tablets Market are Johnson & Johnson, Novartis, Tris Pharma, Lannett Company, Noven Pharmaceuticals, Purdue Parma, Mallinckrodt, Ironshore Pharmaceuticals

What are the Application segmentation covered in the Methylphenidate Extended Release Tablets Market report?

Ans: The Applications covered in the Methylphenidate Extended Release Tablets Market report are Hospital Pharmacy, Retail Pharmacy

What are the Type segmentation covered in the Methylphenidate Extended Release Tablets Market report?

Ans: The Types covered in the Methylphenidate Extended Release Tablets Market report are 18mg, 27mg, 36mg

1 Study Coverage
1.1 Introduction to Methylphenidate Extended Release Tablets: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Methylphenidate Extended Release Tablets Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 18mg
1.2.3 27mg
1.2.4 36mg
1.3 Market Segmentation by Application
1.3.1 Global Methylphenidate Extended Release Tablets Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Methylphenidate Extended Release Tablets Revenue Estimates and Forecasts 2020-2031
2.2 Global Methylphenidate Extended Release Tablets Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Methylphenidate Extended Release Tablets Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Methylphenidate Extended Release Tablets Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 18mg Market Size by Players
3.3.2 27mg Market Size by Players
3.3.3 36mg Market Size by Players
3.4 Global Methylphenidate Extended Release Tablets Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Methylphenidate Extended Release Tablets Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Methylphenidate Extended Release Tablets Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Methylphenidate Extended Release Tablets Market Size by Type (2020-2031)
6.4 North America Methylphenidate Extended Release Tablets Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Methylphenidate Extended Release Tablets Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Methylphenidate Extended Release Tablets Market Size by Type (2020-2031)
7.4 Europe Methylphenidate Extended Release Tablets Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Methylphenidate Extended Release Tablets Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Methylphenidate Extended Release Tablets Market Size by Type (2020-2031)
8.4 Asia-Pacific Methylphenidate Extended Release Tablets Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Methylphenidate Extended Release Tablets Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Methylphenidate Extended Release Tablets Market Size by Type (2020-2031)
9.4 Central and South America Methylphenidate Extended Release Tablets Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Methylphenidate Extended Release Tablets Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Methylphenidate Extended Release Tablets Market Size by Type (2020-2031)
10.4 Middle East and Africa Methylphenidate Extended Release Tablets Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Methylphenidate Extended Release Tablets Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Methylphenidate Extended Release Tablets Product Features and Attributes
11.1.4 Johnson & Johnson Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.1.5 Johnson & Johnson Methylphenidate Extended Release Tablets Revenue by Product in 2024
11.1.6 Johnson & Johnson Methylphenidate Extended Release Tablets Revenue by Application in 2024
11.1.7 Johnson & Johnson Methylphenidate Extended Release Tablets Revenue by Geographic Area in 2024
11.1.8 Johnson & Johnson Methylphenidate Extended Release Tablets SWOT Analysis
11.1.9 Johnson & Johnson Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Business Overview
11.2.3 Novartis Methylphenidate Extended Release Tablets Product Features and Attributes
11.2.4 Novartis Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.2.5 Novartis Methylphenidate Extended Release Tablets Revenue by Product in 2024
11.2.6 Novartis Methylphenidate Extended Release Tablets Revenue by Application in 2024
11.2.7 Novartis Methylphenidate Extended Release Tablets Revenue by Geographic Area in 2024
11.2.8 Novartis Methylphenidate Extended Release Tablets SWOT Analysis
11.2.9 Novartis Recent Developments
11.3 Tris Pharma
11.3.1 Tris Pharma Corporation Information
11.3.2 Tris Pharma Business Overview
11.3.3 Tris Pharma Methylphenidate Extended Release Tablets Product Features and Attributes
11.3.4 Tris Pharma Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.3.5 Tris Pharma Methylphenidate Extended Release Tablets Revenue by Product in 2024
11.3.6 Tris Pharma Methylphenidate Extended Release Tablets Revenue by Application in 2024
11.3.7 Tris Pharma Methylphenidate Extended Release Tablets Revenue by Geographic Area in 2024
11.3.8 Tris Pharma Methylphenidate Extended Release Tablets SWOT Analysis
11.3.9 Tris Pharma Recent Developments
11.4 Lannett Company
11.4.1 Lannett Company Corporation Information
11.4.2 Lannett Company Business Overview
11.4.3 Lannett Company Methylphenidate Extended Release Tablets Product Features and Attributes
11.4.4 Lannett Company Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.4.5 Lannett Company Methylphenidate Extended Release Tablets Revenue by Product in 2024
11.4.6 Lannett Company Methylphenidate Extended Release Tablets Revenue by Application in 2024
11.4.7 Lannett Company Methylphenidate Extended Release Tablets Revenue by Geographic Area in 2024
11.4.8 Lannett Company Methylphenidate Extended Release Tablets SWOT Analysis
11.4.9 Lannett Company Recent Developments
11.5 Noven Pharmaceuticals
11.5.1 Noven Pharmaceuticals Corporation Information
11.5.2 Noven Pharmaceuticals Business Overview
11.5.3 Noven Pharmaceuticals Methylphenidate Extended Release Tablets Product Features and Attributes
11.5.4 Noven Pharmaceuticals Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.5.5 Noven Pharmaceuticals Methylphenidate Extended Release Tablets Revenue by Product in 2024
11.5.6 Noven Pharmaceuticals Methylphenidate Extended Release Tablets Revenue by Application in 2024
11.5.7 Noven Pharmaceuticals Methylphenidate Extended Release Tablets Revenue by Geographic Area in 2024
11.5.8 Noven Pharmaceuticals Methylphenidate Extended Release Tablets SWOT Analysis
11.5.9 Noven Pharmaceuticals Recent Developments
11.6 Purdue Parma
11.6.1 Purdue Parma Corporation Information
11.6.2 Purdue Parma Business Overview
11.6.3 Purdue Parma Methylphenidate Extended Release Tablets Product Features and Attributes
11.6.4 Purdue Parma Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.6.5 Purdue Parma Recent Developments
11.7 Mallinckrodt
11.7.1 Mallinckrodt Corporation Information
11.7.2 Mallinckrodt Business Overview
11.7.3 Mallinckrodt Methylphenidate Extended Release Tablets Product Features and Attributes
11.7.4 Mallinckrodt Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.7.5 Mallinckrodt Recent Developments
11.8 Ironshore Pharmaceuticals
11.8.1 Ironshore Pharmaceuticals Corporation Information
11.8.2 Ironshore Pharmaceuticals Business Overview
11.8.3 Ironshore Pharmaceuticals Methylphenidate Extended Release Tablets Product Features and Attributes
11.8.4 Ironshore Pharmaceuticals Methylphenidate Extended Release Tablets Revenue and Gross Margin (2020-2025)
11.8.5 Ironshore Pharmaceuticals Recent Developments
12 Methylphenidate Extended Release TabletsIndustry Chain Analysis
12.1 Methylphenidate Extended Release Tablets Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Methylphenidate Extended Release Tablets Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Methylphenidate Extended Release Tablets Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Johnson & Johnson
Novartis
Tris Pharma
Lannett Company
Noven Pharmaceuticals
Purdue Parma
Mallinckrodt plc
Ironshore Pharmaceuticals
Johnson & Johnson
List of Tables
 Table 1. Global Methylphenidate Extended Release Tablets Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Methylphenidate Extended Release Tablets Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Methylphenidate Extended Release Tablets Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Methylphenidate Extended Release Tablets Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Methylphenidate Extended Release Tablets Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Methylphenidate Extended Release Tablets Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Methylphenidate Extended Release Tablets Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Methylphenidate Extended Release Tablets by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Methylphenidate Extended Release Tablets as of 2024)
 Table 11. Global Methylphenidate Extended Release Tablets Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Methylphenidate Extended Release Tablets Companies Headquarters
 Table 13. Global Methylphenidate Extended Release Tablets Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Methylphenidate Extended Release Tablets Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Methylphenidate Extended Release Tablets Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Methylphenidate Extended Release Tablets Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Methylphenidate Extended Release Tablets Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Methylphenidate Extended Release Tablets High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Methylphenidate Extended Release Tablets Growth Accelerators and Market Barriers
 Table 25. North America Methylphenidate Extended Release Tablets Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Methylphenidate Extended Release Tablets Growth Accelerators and Market Barriers
 Table 27. Europe Methylphenidate Extended Release Tablets Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Methylphenidate Extended Release Tablets Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Methylphenidate Extended Release Tablets Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Methylphenidate Extended Release Tablets Investment Opportunities and Key Challenges
 Table 31. Central and South America Methylphenidate Extended Release Tablets Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Methylphenidate Extended Release Tablets Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Methylphenidate Extended Release Tablets Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Johnson & Johnson Corporation Information
 Table 35. Johnson & Johnson Description and Major Businesses
 Table 36. Johnson & Johnson Product Features and Attributes
 Table 37. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Johnson & Johnson Revenue Proportion by Product in 2024
 Table 39. Johnson & Johnson Revenue Proportion by Application in 2024
 Table 40. Johnson & Johnson Revenue Proportion by Geographic Area in 2024
 Table 41. Johnson & Johnson Methylphenidate Extended Release Tablets SWOT Analysis
 Table 42. Johnson & Johnson Recent Developments
 Table 43. Novartis Corporation Information
 Table 44. Novartis Description and Major Businesses
 Table 45. Novartis Product Features and Attributes
 Table 46. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Novartis Revenue Proportion by Product in 2024
 Table 48. Novartis Revenue Proportion by Application in 2024
 Table 49. Novartis Revenue Proportion by Geographic Area in 2024
 Table 50. Novartis Methylphenidate Extended Release Tablets SWOT Analysis
 Table 51. Novartis Recent Developments
 Table 52. Tris Pharma Corporation Information
 Table 53. Tris Pharma Description and Major Businesses
 Table 54. Tris Pharma Product Features and Attributes
 Table 55. Tris Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Tris Pharma Revenue Proportion by Product in 2024
 Table 57. Tris Pharma Revenue Proportion by Application in 2024
 Table 58. Tris Pharma Revenue Proportion by Geographic Area in 2024
 Table 59. Tris Pharma Methylphenidate Extended Release Tablets SWOT Analysis
 Table 60. Tris Pharma Recent Developments
 Table 61. Lannett Company Corporation Information
 Table 62. Lannett Company Description and Major Businesses
 Table 63. Lannett Company Product Features and Attributes
 Table 64. Lannett Company Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Lannett Company Revenue Proportion by Product in 2024
 Table 66. Lannett Company Revenue Proportion by Application in 2024
 Table 67. Lannett Company Revenue Proportion by Geographic Area in 2024
 Table 68. Lannett Company Methylphenidate Extended Release Tablets SWOT Analysis
 Table 69. Lannett Company Recent Developments
 Table 70. Noven Pharmaceuticals Corporation Information
 Table 71. Noven Pharmaceuticals Description and Major Businesses
 Table 72. Noven Pharmaceuticals Product Features and Attributes
 Table 73. Noven Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Noven Pharmaceuticals Revenue Proportion by Product in 2024
 Table 75. Noven Pharmaceuticals Revenue Proportion by Application in 2024
 Table 76. Noven Pharmaceuticals Revenue Proportion by Geographic Area in 2024
 Table 77. Noven Pharmaceuticals Methylphenidate Extended Release Tablets SWOT Analysis
 Table 78. Noven Pharmaceuticals Recent Developments
 Table 79. Purdue Parma Corporation Information
 Table 80. Purdue Parma Description and Major Businesses
 Table 81. Purdue Parma Product Features and Attributes
 Table 82. Purdue Parma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Purdue Parma Recent Developments
 Table 84. Mallinckrodt Corporation Information
 Table 85. Mallinckrodt Description and Major Businesses
 Table 86. Mallinckrodt Product Features and Attributes
 Table 87. Mallinckrodt Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Mallinckrodt Recent Developments
 Table 89. Ironshore Pharmaceuticals Corporation Information
 Table 90. Ironshore Pharmaceuticals Description and Major Businesses
 Table 91. Ironshore Pharmaceuticals Product Features and Attributes
 Table 92. Ironshore Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Ironshore Pharmaceuticals Recent Developments
 Table 94. Raw Materials Key Suppliers
 Table 95. Distributors List
 Table 96. Market Trends and Market Evolution
 Table 97. Market Drivers and Opportunities
 Table 98. Market Challenges, Risks, and Restraints
 Table 99. Research Programs/Design for This Report
 Table 100. Key Data Information from Secondary Sources
 Table 101. Key Data Information from Primary Sources


List of Figures
 Figure 1. Methylphenidate Extended Release Tablets Product Picture
 Figure 2. Global Methylphenidate Extended Release Tablets Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. 18mg Product Picture
 Figure 4. 27mg Product Picture
 Figure 5. 36mg Product Picture
 Figure 6. Global Methylphenidate Extended Release Tablets Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospital Pharmacy
 Figure 8. Retail Pharmacy
 Figure 9. Methylphenidate Extended Release Tablets Report Years Considered
 Figure 10. Global Methylphenidate Extended Release Tablets Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Methylphenidate Extended Release Tablets Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Methylphenidate Extended Release Tablets Revenue Market Share by Region (2020-2031)
 Figure 14. Global Methylphenidate Extended Release Tablets Revenue Market Share Ranking (2024)
 Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 16. 18mg Revenue Market Share by Player in 2024
 Figure 17. 27mg Revenue Market Share by Player in 2024
 Figure 18. 36mg Revenue Market Share by Player in 2024
 Figure 19. Global Methylphenidate Extended Release Tablets Revenue Market Share by Type (2020-2031)
 Figure 20. Global Methylphenidate Extended Release Tablets Revenue Market Share by Application (2020-2031)
 Figure 21. North America Methylphenidate Extended Release Tablets Revenue YoY (2020-2031) & (US$ Million)
 Figure 22. North America Top 5 Players Methylphenidate Extended Release Tablets Revenue (US$ Million) in 2024
 Figure 23. North America Methylphenidate Extended Release Tablets Revenue (US$ Million) by Type (2020 - 2031)
 Figure 24. North America Methylphenidate Extended Release Tablets Revenue (US$ Million) by Application (2020-2031)
 Figure 25. US Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 26. Canada Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 27. Mexico Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 28. Europe Methylphenidate Extended Release Tablets Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. Europe Top 5 Players Methylphenidate Extended Release Tablets Revenue (US$ Million) in 2024
 Figure 30. Europe Methylphenidate Extended Release Tablets Revenue (US$ Million) by Type (2020-2031)
 Figure 31. Europe Methylphenidate Extended Release Tablets Revenue (US$ Million) by Application (2020-2031)
 Figure 32. Germany Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 33. France Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 34. U.K. Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 35. Italy Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 36. Russia Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Methylphenidate Extended Release Tablets Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Top 8 Players Methylphenidate Extended Release Tablets Revenue (US$ Million) in 2024
 Figure 39. Asia-Pacific Methylphenidate Extended Release Tablets Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Asia-Pacific Methylphenidate Extended Release Tablets Revenue (US$ Million) by Application (2020-2031)
 Figure 41. Indonesia Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 42. Japan Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 43. South Korea Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 44. Australia Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 45. India Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 46. Indonesia Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 47. Vietnam Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 48. Malaysia Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 49. Philippines Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 50. Singapore Methylphenidate Extended Release Tablets Revenue (2020-2031) & (US$ Million)
 Figure 51. Central and South America Methylphenidate Extended Release Tablets Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Central and South America Top 5 Players Methylphenidate Extended Release Tablets Revenue (US$ Million) in 2024
 Figure 53. Central and South America Methylphenidate Extended Release Tablets Revenue (US$ Million) by Type (2020-2031)
 Figure 54. Central and South America Methylphenidate Extended Release Tablets Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Brazil Methylphenidate Extended Release Tablets Revenue (2020-2025) & (US$ Million)
 Figure 56. Argentina Methylphenidate Extended Release Tablets Revenue (2020-2025) & (US$ Million)
 Figure 57. Middle East and Africa Methylphenidate Extended Release Tablets Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Top 5 Players Methylphenidate Extended Release Tablets Revenue (US$ Million) in 2024
 Figure 59. South America Methylphenidate Extended Release Tablets Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Middle East and Africa Methylphenidate Extended Release Tablets Revenue (US$ Million) by Application (2020-2031)
 Figure 61. GCC Countries Methylphenidate Extended Release Tablets Revenue (2020-2025) & (US$ Million)
 Figure 62. Israel Methylphenidate Extended Release Tablets Revenue (2020-2025) & (US$ Million)
 Figure 63. Egypt Methylphenidate Extended Release Tablets Revenue (2020-2025) & (US$ Million)
 Figure 64. South Africa Methylphenidate Extended Release Tablets Revenue (2020-2025) & (US$ Million)
 Figure 65. Methylphenidate Extended Release Tablets Industry Chain Mapping
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Methylphenidate Hydrochloride Extended Release Tablets Market Research Report 2025
Global Methylphenidate for ADHD Treatment Market Research Report 2024
Methylphenidate Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Methylphenidate Transdermal Patches Market Research Report 2025
Global ADHD Drug Treatment Market Research Report 2024
Extended release Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Adult ADHD Treatment Market Research Report 2024
Global Guanfacine Extended Release Pill Market Research Report 2024
Global Psychostimulants Market Research Report 2024
Global Methylphenidate Hydrochloride Market Research Report 2024
Global Children ADHD Treatment Market Research Report 2024
Global ADHD Medications Market Insights Forecast to 2030
Global Atomoxetine Hydrochloride Capsules Market Research Report 2024
Global Attention deficit Hyperactivity Disorder ADHD Therapeutics Market Research Report 2024
Global Bupropion Hydrochloride Extended Release Tablets Market Research Report 2025
Global Anti Adhd Supplements Market Research Report 2024
Global Metformin Hydrochloride Sustained release Tablets Market Research Report 2024
ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Attention Deficit Hyperactivity Disorder Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Attention Deficit Hyperactivity Syndrome Treatment Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions